Do terazosin and finasteride provide greater efficacy when used together for benign prostatic hyperplasia?

Combination Therapy of Terazosin and Finasteride for BPH

Terazosin and finasteride do NOT work better together—terazosin alone is equally effective as the combination for symptom improvement, and adding finasteride provides no additional benefit in the short term. 1

Evidence from Clinical Trials

The landmark Veterans Affairs Cooperative Study directly compared terazosin, finasteride, combination therapy, and placebo in 1,229 men with BPH over one year. The results were definitive:

• Terazosin alone decreased symptom scores by 6.1 points and increased peak flow by 2.7 mL/second 1
• Combination therapy decreased symptom scores by 6.2 points and increased peak flow by 3.2 mL/second 1
• Finasteride alone was no more effective than placebo, with only a 3.2-point symptom improvement 1

The differences between terazosin monotherapy and combination therapy were not statistically or clinically significant for symptom improvement, quality of life, or patient-reported outcomes. 2

FDA-Approved Indications Support Combination Only with Doxazosin

The FDA label for finasteride specifically indicates combination therapy only with doxazosin (not terazosin) to reduce risk of symptomatic BPH progression. 3 Terazosin's FDA label makes no mention of combination therapy with finasteride. 4

When Combination Therapy May Be Considered

For long-term disease progression prevention (not symptom relief), combination therapy with an alpha-blocker and 5-ARI has demonstrated benefit, but this evidence comes from studies using doxazosin + finasteride, not terazosin + finasteride:

• The MTOPS trial showed combination doxazosin + finasteride reduced clinical progression by 66% versus placebo, superior to either drug alone 5
• This benefit was primarily in preventing acute urinary retention and need for surgery 5

Current Guideline Recommendations

The 2021 AUA guidelines recommend 5-ARI + alpha-blocker combination therapy only for patients with demonstrable prostatic enlargement (prostate volume >30cc, PSA >1.5 ng/mL, or palpable enlargement on DRE). 6 This is a strong recommendation based on Grade A evidence. 6

The 2023 EAU guidelines reference the CombAT study (dutasteride + tamsulosin) showing superior outcomes with combination therapy at 4 years. 7

Clinical Algorithm

For immediate symptom relief:

• Use terazosin monotherapy—adding finasteride provides no additional benefit 1, 2

For long-term progression prevention in men with enlarged prostates (>30cc):

• Consider combination therapy with an alpha-blocker + 5-ARI, but recognize the evidence specifically supports doxazosin + finasteride or tamsulosin + dutasteride, not terazosin + finasteride 6, 5

For men with smaller prostates (<30cc):

• Finasteride provides no benefit even in combination 8

Important Caveats

• Finasteride requires long-term use (>1 year) to show any benefit over placebo 9
• The combination increases adverse effects: finasteride adds sexual dysfunction (impotence, decreased libido, ejaculation disorder), while terazosin adds dizziness and postural hypotension 1, 10
• Patient-reported improvement rates were 61% for terazosin alone versus 65% for combination—a clinically insignificant difference 2